This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Andes, D.
Right arrow Articles by Conklin, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andes, D.
Right arrow Articles by Conklin, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2003, p. 1187-1192, Vol. 47, No. 4
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.4.1187-1192.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vivo Pharmacodynamics of HMR 3270, a Glucan Synthase Inhibitor, in a Murine Candidiasis Model

D. Andes,1,2* K. Marchillo,2 J. Lowther,3 A. Bryskier,3 T. Stamstad,2 and R. Conklin2

University of Wisconsin,1 William S. Middleton VA Hospital, Madison, Wisconsin,2 Aventis Pharmaceuticals, Romainville, France3

Received 7 January 2002/ Returned for modification 12 October 2002/ Accepted 30 December 2002

In vivo pharmacokinetic/pharmacodynamic characterization for numerous antibacterial compounds has had a significant impact upon optimal dosing regimen design and the development of in vivo susceptibility breakpoints. More recently, similar characterization has been undertaken for antifungal drug classes. Very little is known of these pharmacodynamic relationships for the new echinocandin class of compounds. We utilized a neutropenic murine model of disseminated candidiasis to describe the time course antifungal activity of HMR 3270, a new glucan synthase inhibitor. Single-dose in vivo time kill studies with four 16-fold escalating doses demonstrated concentration-dependent killing when drug levels in serum were more than four times the MIC. Postantifungal effects were dose dependent, ranging from 8 to 80 h duration. Multiple dosing regimen studies utilized six total doses, four dosing intervals, and a treatment duration of 6 days. Shortening the dosing interval from every 144 h (q144h) to q36h resulted in a fourfold rise in the dose necessary to achieve a net fungistatic effect. The peak/MIC ratio most strongly correlated with treatment outcomes (peak/MIC ratio, R2 = 98%; ratio of the area under the concentration-time curve from 0 to 24 h to the MIC, R2 = 79%, percentage of time above the MIC, R2 = 61%). Studies were also conducted with five additional Candida albicans isolates to determine if a similar peak/MIC ratio was associated with efficacy. In vivo concentration-dependent killing was similarly observed in studies with each of the additional isolates. The peak/MIC ratio necessary to produce efficacy was relatively similar among the strains studied (P = 0.42). The peak/MIC ratio (mean ± standard deviation) necessary to achieve a fungistatic effect was 3.72 ± 1.84, and the ratio necessary to achieve maximal killing was near 10.

* Corresponding author. Mailing address: University of Wisconsin, 600 Highland Ave., Room H4/572, Madison, WI 53792. Phone: (608) 263-1545. Fax: (608) 263-4464. E-mail: dra{at}medicine.wisc.edu.

Antimicrobial Agents and Chemotherapy, April 2003, p. 1187-1192, Vol. 47, No. 4
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.4.1187-1192.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • van de Sande, W. W. J., Mathot, R. A. A., ten Kate, M. T., van Vianen, W., Tavakol, M., Rijnders, B. J. A., Bakker-Woudenberg, I. A. J. M. (2009). Combination Therapy of Advanced Invasive Pulmonary Aspergillosis in Transiently Neutropenic Rats Using Human Pharmacokinetic Equivalent Doses of Voriconazole and Anidulafungin. Antimicrob. Agents Chemother. 53: 2005-2013 [Abstract] [Full Text]  
  • Brzankalski, G. E., Najvar, L. K., Wiederhold, N. P., Bocanegra, R., Fothergill, A. W., Rinaldi, M. G., Pattterson, T. F., Graybill, J. R. (2008). Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. J Antimicrob Chemother 62: 1094-1100 [Abstract] [Full Text]  
  • Andes, D. R., Diekema, D. J., Pfaller, M. A., Marchillo, K., Bohrmueller, J. (2008). In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model. Antimicrob. Agents Chemother. 52: 3497-3503 [Abstract] [Full Text]  
  • Andes, D., Diekema, D. J., Pfaller, M. A., Prince, R. A., Marchillo, K., Ashbeck, J., Hou, J. (2008). In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model. Antimicrob. Agents Chemother. 52: 539-550 [Abstract] [Full Text]  
  • Pasqualotto, A. C., Denning, D. W. (2008). New and emerging treatments for fungal infections. J Antimicrob Chemother 61: i19-i30 [Abstract] [Full Text]  
  • Gumbo, T., Drusano, G. L., Liu, W., Kulawy, R. W., Fregeau, C., Hsu, V., Louie, A. (2007). Once-Weekly Micafungin Therapy Is as Effective as Daily Therapy for Disseminated Candidiasis in Mice with Persistent Neutropenia. Antimicrob. Agents Chemother. 51: 968-974 [Abstract] [Full Text]  
  • Ghannoum, M. A., Kim, H. G., Long, L. (2007). Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis. J Antimicrob Chemother 59: 556-559 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J. (2007). Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin. Microbiol. Rev. 20: 133-163 [Abstract] [Full Text]  
  • Morris, M. I., Villmann, M. (2006). Echinocandins in the management of invasive fungal infections, part 1.. Am J Health Syst Pharm 63: 1693-1703 [Abstract] [Full Text]  
  • Louie, A., Deziel, M., Liu, W., Drusano, M. F., Gumbo, T., Drusano, G. L. (2005). Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity. Antimicrob. Agents Chemother. 49: 5058-5068 [Abstract] [Full Text]  
  • Walsh, T. J., Adamson, P. C., Seibel, N. L., Flynn, P. M., Neely, M. N., Schwartz, C., Shad, A., Kaplan, S. L., Roden, M. M., Stone, J. A., Miller, A., Bradshaw, S. K., Li, S. X., Sable, C. A., Kartsonis, N. A. (2005). Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents. Antimicrob. Agents Chemother. 49: 4536-4545 [Abstract] [Full Text]  
  • Warn, P. A., Sharp, A., Morrissey, G., Denning, D. W. (2005). Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis. J Antimicrob Chemother 56: 590-593 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»